Global Germ Cell Tumor Treatment Market 2023-2030

Overview

A germ cell tumor is a mass made of reproductive cells, also called germ cells. Germ is short for germinate, which means to mature. For women and people assigned female at birth (AFAB), germ cells eventually mature into eggs. For men and people assigned male at birth (AMAB), germ cells mature into sperm. Related, germ cell tumors are mainly seen in ovaries and testicles. Less commonly, germ cell tumors form in body parts other than ovaries and testicles, including the abdomen, chest, lower back, head and neck and brain. These tumors are called extragonadal tumors.

Moreover, surgery is the primary treatment for germ cell tumors. Most germ cell tumors are treated with chemotherapy or a combination of chemotherapy and radiation therapy. It is estimated that germ cell tumors in children are rare, making up only 3.5% of cancer diagnoses. They are more common in adolescents and young adults, making up 13.9% of cancers diagnosed between ages 15 to 19.

Market Dynamics: Drivers

Increasing demand for novel therapeutics

The increasing demand for novel therapeutics for the treatment of germ cell tumors is expected to drive the market over the forecast period. The germ cell tumors includes various types of ovarian, testicular and extragonadal cancers. The development of novel therapeutics helps to address unmet medical needs and results in better patient outcomes. Even, biosimilars plays a crucial role in the treatment of various types of germ cell tumors, biosimilars offers patients lower-cost medicines, often making these treatments more accessible and improving quality of life

For instance, on May 29, 2023, Alkem Oncology launched Cetuxa, the world's first biosimilar of Cetuximab used for the treatment of head and neck cancer. Cetuxa has been researched and manufactured indigenously by Enzene Biosciences Limited, the biological arm of Alkem Laboratories.

In addition, the regulatory approvals increase the trust in patients about the development of novel therapeutics. For instance, on May 09, 2023, Acrivon Therapeutics, Inc. released that the company has been granted two Fast Track designations by the U.S. Food and Drug Administration (FDA) for the development of ACR-368 in platinum-resistant ovarian cancer and endometrial cancer. Fast Track designation is intended to facilitate the development and expedite the review of promising investigational drugs to treat serious conditions with significant unmet medical needs.

Moreover, many clinical trials are going on for the development of novel therapeutics like cell therapies, which shows better results in the treatment of germ cell tumors. For instance, on August 28, 2023, Anixa Biosciences, Inc., a biotechnology company focused on the treatment and prevention of cancer, in partnership with Moffitt Cancer Center, commenced treatment of the third patient in the ongoing clinical trial of Anixa's novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

Additionally, the novel therapeutics also improves the treatment outcomes by the combination drugs, many research activities and approvals are going on about the combination treatments for better patient outcomes. For instance, on April 17, 2023 HUTCHMED (China) Limited released its New Drug Application for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric or gastroesophageal junction adenocarcinoma in China has been accepted for review by the China National Medical Products Administration (NMPA).

Further, the increasing prevalence of germ cell tumors like ovarian cancer, testicular cancer, head and neck cancers, abdominal cancers and others, rising FDA approvals, increasing clinical trials, increasing awareness and advancements in the development of novel drugs and therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the treatment, the high cost of the treatment of germ cell tumors and the availability of alternative treatment options are expected to hamper the market.

Segment Analysis

The global germ cell tumor treatment market is segmented based on tumor type, treatment type, end-user and region.

The surgery segment accounted for approximately 34.9% of the germ cell tumor treatment market share

The surgery segment is expected to hold the largest market share over the forecast period. Surgery is considered as a primary treatment for germ cell tumors. Surgery removes the tumor from the affected ovary (ovarian cystectomy) or the entire ovary and fallopian tubes (salpingo-oophorectomy). With testicular cancer, the testicle with the tumor is removed by radical inguinal orchiectomy.

For instance, according to NYU Langone Health, surgery alone can cure some malignant germ cell tumors in the gonads such as ovaries and testicles. For germ cell tumors in the testicles, a surgeon removes the tumor and one or both testicles through a small incision in the groin. For ovarian germ cell tumors, which typically appear on one ovary, the surgeon removes the tumor, the ovary, and the fallopian tube through a small incision in the abdomen. Leaving one ovary or testicle when possible can help preserve fertility.

Moreover, for many early-stage germ cell tumors, surgery can be curative. If the cancer is localized and hasn't spread, complete removal of the tumor through surgery may eliminate the cancer and provide a potential cure. Surgery is often complemented by adjuvant therapies such as chemotherapy or radiation, especially in cases where the cancer has advanced or has a higher risk of recurrence. The combination of treatments aims to maximize effectiveness.

Geographical Analysis

North America accounted for approximately 41.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America, especially in the United States is home to numerous major pharmaceutical and biotechnology companies that are actively involved in germ cell cancer research and the development of oncology treatments. The presence of these key players contributes to the region's dominance in the germ cell tumor treatment market.

For instance, on July 27, 2023, Anixa Biosciences, Inc., a biotechnology company focused on the treatment and prevention of cancer, released that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance broadening protection of Anixa's novel ovarian cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic.

Furthermore, the region is also known for its advanced healthcare facilities for better treatment by using advanced therapies. The region's advanced healthcare infrastructure plays a crucial role in performing research activities and clinical trials for the development of advanced treatment options. As the research activities increase, combination therapeutics are developed more precisely by reducing the adverse effects and complications associated with the therapeutics, which results in better patient outcomes.

In addition, on January 9, 2023, Sonnet BioTherapeutics Holdings, Inc. collaborated on the agreement with Roche. A clinical trial (SB221) will be conducted to assess the safety and preliminary efficacy of SON-1010 (IL12-FHAB) in combination with Roche's atezolizumab in patients with platinum-resistant ovarian cancer (PROC). Interleukin-12 (IL-12) is a cytokine, or an immune cell-signaling protein, that enhances the activity of natural killer (NK) cells and T cells. The combination of these two agents in an indication that persists as a large unmet medical need.

Competitive Landscape

The major global players in the germ cell tumor treatment market include: GlaxoSmithKline plc, Merck KGaA, AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Novartis AG, Amgen Inc., Accord Healthcare Limited, GLS Pharma Pvt. Ltd. And Cadila Pharmaceuticals among others.

Key Developments

• On July 6, 2023, Astellas Pharma Inc. cleared that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's Biologics License Application (BLA) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. If approved, zolbetuximab would be the first CLDN18.2-targeted therapy available in the U.S. for these patients.
• On November 14, 2022, ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, released that the US Food and Drug Administration (FDA) has granted accelerated approval for ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global germ cell tumor treatment market. During the pandemic, due to concerns about COVID-19 virus exposure and healthcare system strain, some individuals may have delayed seeking medical attention for symptoms, leading to later-stage diagnoses and potentially impacting the effectiveness of treatment of germ cell tumors. The pandemic disrupted many clinical trials related to germ cell tumors due to the redirected focus towards COVID-19. This could have slowed down the development and approval of new therapies for germ cell tumors.

Why Purchase the Report?

• To visualize the global germ cell tumor treatment market segmentation based on tumor type, treatment type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of germ cell tumor treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global germ cell tumor treatment market report would provide approximately 61 tables, 59 figures, and 187 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies